Biogen, Talkiatry offer services to patients with postpartum depression: We examine whether drugmaker-telehealth tie-ups are what’s best for patients.
Activist investor takes $1B stake in Pfizer, eyes a performance turnaround: But to the drugmaker’s credit, its plan to diversify the therapeutic areas it will focus on moving forward should place it in line with investors’ expectations.
Patient care is being disrupted by cyberattacks: Cyberattacks aren’t just causing financial disruptions—they’re causing real patient harm, too.
CA governor signs two healthcare AI bills into law: Lawmakers believe AI should be used as a supplementary tool when it comes to patient care.
More bad news for Medicare Advantage insurers: Humana’s huge drop in star ratings is another indicator that MA plans will likely cut seniors’ benefits in the future.
The Epic, Particle Health saga unpacked: Particle’s recent filing of an antitrust lawsuit raises salient points on patient data privacy and anti-competitive behavior in healthcare.
Consumers’ telehealth satisfaction varies from visit to visit: We explore the competitive telehealth market and examine how virtual care players are adapting to remain viable.
Eli Lilly’s GLP-1 medication shortage ends: The host of players who offer compounded versions of the blockbuster drugs don’t have to worry—yet.
Blue Shield of California negotiates for cheaper version of biosimilar: This is the first time a health insurer has used this approach to bring a Humira biosimilar to market, circumventing pharmacy benefit managers entirely.
US voters want presidential candidates to address high healthcare costs: We think each campaign will make this a priority over the next month.
Ad spending projects to hold strong in healthcare and pharma: Here’s why health and pharma marketers are prioritizing some media channels over others.
A focus on longer battery life and lighter design could secure a lead over Samsung in the high-growth wearables market.
CVS Health explores possible company breakup: A series of concurrent headwinds are impacting multiple sectors of CVS Health’s business, leading concerned investors to step in and try to force its hand.
Docs deem AI Overviews a risky source of medical information: AI-generated summaries of users’ health searches are imperfect. They’ll need to get better given consumers' many options to obtain health info.
Doctors are using genAI to respond to their patients’ MyChart messages: But patients aren’t always aware, which can erode the trust underpinning the patient-physician relationship.
TikTok, World Health Organization join forces to combat medical misinformation: After being scrutinized for the impact that misinformation on its platform has had on younger users, TikTok is taking a page out of YouTube’s book to fight it.
Most patients are anxious before going to the doctor: But they settle in once they’re in the appointment. We explore how healthcare marketers and providers could use these patient sentiments to their advantage.
9amHealth, Instacart tackle obesity with healthy food and GLP-1s: We think that employer and health plan customers will be pleased with the program’s less costly approach than prescription weight loss drugs alone.
Global consumers feel pressured by society to improve their well-being: Marketers have a unique opportunity to re-write the narrative of the well-being space with a lighter spin.
FTC sues drug middlemen for artificially inflating insulin prices: FTC Chair Lina Khan is coming after pharmacy benefit managers while delivering a shot across the bow to the entire pharmaceutical industry.